Clinical Trial Update: Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). [Phase 3]

View source ↗

Summary

Phase 3 COMBI-AD trial update reports results for dabrafenib plus trametinib as adjuvant treatment in high-risk BRAF V600 mutation-positive melanoma; results we…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• MEKINIST (trametinib)
• TAFINLAR (DABRAFENIB)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Melanoma | Phase 3 | Status: COMPLETED | Results posted: 2018-09-26